title: [Postmenopausal osteoporosis: Primary prevention or excessive use of medications].
abstract: OBJECTIVE
  [corrected] Estimate the percentage of excessive use of medicines (bisphosponates, strontium ranelate and raloxifene) in the prevention of fragility fractures in postmenopausal women.
  
  
  METHODS
  A descriptive study conducted in an urban health centre in Vitoria-Gasteiz. The participants were women aged between 50 and 70, treated during 2010 with some of aforementioned medicines. Out of the 253 women included, three died, two moved, one did not want to sake part, and another one could not be found, leaving 246 participants. It was determinated if the treatment was or not indicated, as recommended in the ESCEO, NAMS and NOF clinical practice guides. A data search, including fragility fracture history, densitometry performed, densitometry diagnoses, prescribed medicines and prescribing doctor, was carried out by looking in the Osabide and Global Clinic digital clinic records. Interviews were carried out with 72 patients for a more complete information.
  
  
  RESULTS
  The mean patient age was 60.5 ± 4.9 years, and 91,5% of them (225) had undergone a densitometry. Three-quarters (75.1%, 169) had a diagnosis of osteoporosis and 4,4% (11) had previous history of fractures. More than a quarter (27.0%, 68) of treatments had no indication, and varied depending of the prescribing doctor (family doctors: 8.5%/ traumatologists: 58.5%) (p<0.001). The use of the medicine of choice, alendronate in 29.7% of cases, Was significantly higher (59.3%) in Primary Care than in other specialties.
  
  
  CONCLUSIONS
  A high percentage of women are given excessive medication, exposing them to potentially severe secondary damages. Family doctors deal correctly with osteoporosis, with a high percentage of indicated treatments and a rational use of medicines, with alendronate as the first choice in the majority of cases.
authors.affiliation: Medicina de Familia y Comunitaria, Centro de Salud Aranbizkarra II, Vitoria-Gasteiz, España. concha.mendozaedroso@osakidetza.net
authors.forename: C
authors.initials: C
authors.lastname: Mendoza-Edroso
authors.forename: N
authors.initials: N
authors.lastname: Sánchez Garrido-Lestache
authors.forename: A
authors.initials: A
authors.lastname: Lopez-Picado
mesh_terms: D000368:Aged; D003430:Cross-Sectional Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D011322:Primary Prevention; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D004164:Diphosphonates; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate; D020849:Raloxifene Hydrochloride